第7章 資訊來源

附錄

圖表一覽

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Product Code: CP1011

Executive Summary

The ‘Top 50 Big Biotech Partnering and M&A Deal Trends 2010-2015’ report provides the most comprehensive and in-depth insight into the dealmaking activity of the world's leading fifty biotech companies.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 300 charts allow quick understanding of each big biotech companies dealmaking trends over the last four years.

The initial chapters of this report provide an orientation of big biotech's dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2012 pharmaceutical revenues and dealmaking activity since 2010.

Chapter 3 reviews the top partnering and M&A deals of 2010-2015 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big biotech, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big biotech provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big biotech company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partner's negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This data driven report contains over 2,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right big biotech partners effectively and efficiently.

Report scope

‘Top 50 Big Biotech Partnering and M&A deal Trends’ is intended to provide the reader with an in-depth understanding of the partnering activities of the leading fifty big biotech companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's partnering.

‘Top 50 Big Biotech Partnering and M&A deal Trends’ includes:

Detailed company profiles for each of the top 50 big biotech companies, including: o Partnering interests and indications

Partnering activity since 2010

Partner companies since 2010

Partnering activity since 2010 by:

Partner company

Deal type

Industry sector

Stage of development

Technology type

Therapy area

Over 300 charts showing the dealmaking activity of each company since 2010

The tools to enable effective and efficient preparation for partnering negotiation with big biotech

1,500 partnering deals as recorded at Current Agreement, together with contract documents if available

The leading M&A and partnering deals by value 2010-2015

The ‘Top 50 Big Biotech Partnering and M&A deal Trends’ report also provides comprehensive access to available contract documents for each of the fifty big biotech companies. Analyzing actual company agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subscontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?